Table 2.
Characteristics of 130 patients with VAP with regard to the adequacy of empirical antibiotic treatment
| Characteristics | Adequate treatment n = 44 | Inadequate treatment n = 86 | p |
|---|---|---|---|
| Age (years) |
65.64 ± 16.42 |
64.15 ± 16.83 |
0.628 |
| Sex (male) |
29 (65.9) |
48 (55.8) |
0.358 |
| Surgical unit |
22 (45.8) |
26 (54.2) |
0.044 |
| Underlying diseases |
|
|
|
| Diabetes mellitus |
6 (13.6) |
13 (15.1) |
1.000 |
| COPD |
15(34.1) |
18 (20.9) |
0.156 |
| Chronic renal failure |
1 (2.3) |
4 (4.7) |
0.672 |
| Congestive heart failure |
7 (15.9) |
15 (17.4) |
1.000 |
| Cerebrovascular disease |
5 (11.4) |
16 (18.6) |
0.418 |
| Malignancy |
6 (13.6) |
13 (15.1) |
1.000 |
| Central venous catheterization |
34 (77.3) |
62 (72.1) |
0.671 |
| Urinary catheterization |
43 (97.7) |
84 (97.7) |
1.000 |
| Late-onset VAP |
36 ( 81.8) |
75 (87.2) |
0.575 |
| Presence of other site infection |
12 (27.3) |
42 (48.8) |
0.030 |
| Previous antibiotic usage |
12 (27.3) |
39 (45.3) |
0.071 |
| Culture proven pneumonia |
37 (84.1) |
80 (93.0) |
0.128 |
| Polymicrobial etiology |
2 (4.5) |
6 (7.0) |
0.186 |
| MDR bacteria |
32 (72.7) |
60 (69.8) |
0.883 |
| Length of stay before VAP |
12.61 ± 11.20 |
14.31 ± 10.348 |
0.138 |
| APACHE II score | 16.39 ± 6.71 | 16.81 ± 6.63 | 0.730 |